Articles

This section provides a brief overview of new cancer drugs or new indications approved by the FDA between April 17, 2020, and May 8, 2020. Read More ›

Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation By Wayne Kuznar

By Wayne Kuznar

Colorectal Cancer

TON - June 2020, Vol 13, No 3

Universal CAR T-Cells a Promising Off-the-Shelf Therapy for T-Cell Acute Lymphoblastic Leukemia

By Wayne Kuznar

AACR Highlights

TON - June 2020, Vol 13, No 3

I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study

By Phoebe Starr

AACR Highlights, Breast Cancer

TON - June 2020, Vol 13, No 3

“The idea behind the combination was to boost the immune response by adding an anti–PD-1 checkpoint inhibitor, since PARP inhibitors are known to increase the expression of the PD-L1 protein in the tumor,” said Lajos Pusztai, MD, DPhil. Read More ›

Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma

By Phoebe Starr

Renal Cell Carcinoma

TON - June 2020, Vol 13, No 3

International Society of Cannabis Pharmacists Plans to Hold Inaugural Meeting in 2020

By Meg Barbor, MPH

Medical Marijuana

TON - June 2020, Vol 13, No 3

ASCO Publishes First Guideline on Use of Molecular Biomarkers in Localized Prostate Cancer

By Rebecca Bailey

Biomarkers, Prostate Cancer

TON - June 2020, Vol 13, No 3

The American Society of Clinical Oncology, in partnership with the European Association of Urology, the American Urological Association, and the College of American Pathologists, published a set of recommendations that offers further guide prostate cancer management. Read More ›

Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation

By Wayne Kuznar

Pancreatic Cancer

TON - June 2020, Vol 13, No 3

“The doublet is our recommendation for moving forward, and we believe these data define a reference regimen for germline BRCA-mutated, PALB2-mutated pancreas cancer,” said Eileen M. O’Reilly, MD. Read More ›